Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role

•After reviewing the recent literature and combining it with clinical trials, we found that patients still had many residual cardiovascular risks even with standard atherosclerosis treatment regiments.•The search for treatments for atherosclerosis is far from over.•This study investigated the effect of SGLT2 inhibitor on vascular atherosclerosis after removing the effect of diabetes,focusing on positive significance for the treatment of atherosclerotic diseases.